Literature DB >> 33125159

Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects.

Dennis M de Graaf1,2, Martin Jaeger2, Inge C L van den Munckhof2, Rob Ter Horst2, Kiki Schraa2, Jelle Zwaag3, Matthijs Kox3, Mayumi Fujita4, Takeshi Yamauchi4, Laura Mercurio5, Stefania Madonna5, Joost H W Rutten2, Jacqueline de Graaf2, Niels P Riksen2, Frank L van de Veerdonk2, Mihai G Netea2, Leo A B Joosten2, Charles A Dinarello1,2.   

Abstract

The IL-1 family member IL-38 (IL1F10) suppresses inflammatory and autoimmune conditions. Here, we report that plasma concentrations of IL-38 in 288 healthy Europeans correlate positively with circulating memory B cells and plasmablasts. IL-38 correlated negatively with age (p = 0.02) and was stable in 48 subjects for 1 year. In comparison with primary keratinocytes, IL1F10 expression in CD19+ B cells from PBMC was lower, whereas cell-associated IL-38 expression was comparable. In vitro, IL-38 is released from CD19+ B cells after stimulation with rituximab. Intravenous LPS in humans failed to induce circulating IL-38, compared to 100-fold induction of IL-6 and IL-1 receptor antagonist. In a cohort of 296 subjects with body mass index > 27 at high risk for cardiovascular disease, IL-38 plasma concentrations were significantly lower than in healthy subjects (p < 0.0001), and lowest in those with metabolic syndrome (p < 0.05). IL-38 also correlated inversely with high sensitivity C-reactive protein (p < 0.01), IL-6, IL-1Ra, and leptin (p < 0.05). We conclude that a relative deficiency of the B cell product IL-38 is associated with increased systemic inflammation in aging, cardiovascular and metabolic disease, and is consistent with IL-38 as an anti-inflammatory cytokine.
© 2020 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.

Entities:  

Keywords:  B cells; Cardiovascular disease risk; IL-38; Inflammation; Obesity

Year:  2020        PMID: 33125159     DOI: 10.1002/eji.201948390

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Interleukin 38 alleviates aortic valve calcification by inhibition of NLRP3.

Authors:  Erlinda The; Dennis M de Graaf; Yufeng Zhai; Qingzhou Yao; Lihua Ao; David A Fullerton; Charles A Dinarello; Xianzhong Meng
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

2.  IL-38 Gene Deletion Worsens Murine Colitis.

Authors:  Dennis M de Graaf; Ruth X Wang; Jesús Amo-Aparicio; J Scott Lee; Alexander S Dowdell; Isak W Tengesdal; Carlo Marchetti; Sean P Colgan; Leo A B Joosten; Charles A Dinarello
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

Review 3.  Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study.

Authors:  Abdolreza Esmaeilzadeh; Nazila Bahmaie; Elham Nouri; Mohammad Javad Hajkazemi; Maryam Zareh Rafie
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

4.  Evaluation of interleukin-38 levels in serum of patients with coronavirus disease 2019.

Authors:  Wasan W Al-Bassam; Ibtihal A Al-Karaawi; Inas K Sharquie; Ali H Ad'hiah
Journal:  J Med Virol       Date:  2022-04-14       Impact factor: 20.693

Review 5.  An overview of the biological and multifunctional roles of IL-38 in different infectious diseases and COVID-19.

Authors:  Pooria Fazeli; Mohammadreza Saeidnia; Mehran Erfani; Mehdi Kalani
Journal:  Immunol Res       Date:  2022-03-08       Impact factor: 2.829

6.  Circulating interleukin-38 concentrations in healthy adults.

Authors:  Lisa U Teufel; Dennis M de Graaf; Mihai G Netea; Charles A Dinarello; Leo A B Joosten; Rob J W Arts
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

Review 7.  Interleukin-22: a potential therapeutic target in atherosclerosis.

Authors:  Jin-Wen Luo; Yuan Hu; Jian Liu; Huan Yang; Peng Huang
Journal:  Mol Med       Date:  2021-08-13       Impact factor: 6.354

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.